The short answer
The IGF-1 receptor and the insulin receptor are structurally related, and cells expressing both can assemble hybrid receptors containing subunits of each. That relatedness means neither ligand is entirely selective for its own receptor.
Key facts
- Relationship
- Structurally homologous receptors
- Hybrids
- Contain subunits of both
- Consequence
- Selectivity is relative, not absolute
- Chimeric receptor work
- Schäffer 1993 (PMID 8428981)
- Journal
- J Biol Chem, 15 February 1993
- Practical relevance
- Glucose handling, oncology targeting
Why the two receptors resemble each other
Insulin and IGF-1 are themselves structurally related, as the name insulin-like growth factor records directly. Both descend from a common ancestral system, and their receptors descend alongside them. Shared ancestry produces shared architecture, and shared architecture produces overlapping ligand recognition.
What a hybrid receptor is
Both receptors assemble from subunit pairs. In a cell expressing both, assembly can mix them, producing a receptor with one half from each. Hybrids have their own binding characteristics, distinct from either parent receptor, and their abundance depends on the relative expression of the two in that cell. The pharmacology therefore becomes cell-type dependent.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
How the relationships were mapped
By building chimeric receptors and hybrid ligands and testing which combinations bind. Schäffer and colleagues examined interactions of a hybrid insulin and IGF-I analogue with chimeric insulin and type I IGF receptors in the Journal of Biological Chemistry in 1993. Swapping defined regions between two related molecules and observing what changes is how the determinants of selectivity get identified.
Why this matters for glucose
IGF-1 engaging insulin receptors, or hybrids, produces insulin-like metabolic effects. That is a documented property of the system rather than a hypothetical, and it means anything raising free IGF-1 availability has a route to affecting glucose handling that is separate from its growth-related effects.
Why it complicated the oncology programmes
Blocking IGF-1R without touching insulin receptors or hybrids is difficult because of the structural similarity. That is one of the reasons anti-IGF-1R development proved harder than the biology suggested. The target could not be engaged cleanly, and disturbing insulin signalling has immediate consequences.
What follows for an engineered analogue
An analogue designed to increase free IGF-1 increases engagement of whatever that free IGF-1 reaches, which includes insulin receptors and hybrids in proportion to their local abundance. Selectivity is a property of the receptor landscape as much as of the molecule, and it cannot be fully specified from the sequence alone.
Frequently asked questions
Why does this matter?
It means selectivity is relative. IGF-1 engaging insulin receptors or hybrids produces insulin-like metabolic effects, and it complicated IGF-1R oncology targeting.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSchäffer L et al., Interactions of a hybrid insulin/insulin-like growth factor-I analog with chimeric insulin/type I insulin-like growth factor receptors. J Biol Chem 1993 (PMID 8428981)pubmed.ncbi.nlm.nih.gov
- PubMedChen HX, IGF-1R as an anti-cancer target: trials and tribulations. Chin J Cancer 2013 (PMID 23601239)pubmed.ncbi.nlm.nih.gov
- PubMedYee D, Anti-insulin-like growth factor therapy in breast cancer. J Mol Endocrinol 2018 (PMID 29378771)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- Eighty-Three Residues, and What That ChangesRegulators treat 40 amino acids as the boundary between peptide and protein. At 83 residues, IGF-1 LR3 is well past it - with consequences.
- What Is IGF-1 LR3? Why It Is a Protein, Not a PeptideAn 83-residue engineered IGF-1 analogue built to evade binding proteins. Why it is a protein rather than a peptide, and what that changes.
- IGF Binding Proteins and the Free FractionMost circulating IGF-1 is sequestered in a ternary complex with IGFBP-3 and the acid-labile subunit. That system is what LR3 was designed to evade.
- IGF-1 LR3 Structure: Three Disulfides and Why They Matter83 residues folded by three disulfide bonds. Milner 1995 showed B-domain mutations affect oxidative folding - and position 3 is in the B-domain.
- Recombinant Versus Synthetic: Two Different Quality ProblemsA recombinant protein has host cell proteins, DNA and endotoxin as impurities. A synthetic peptide has deletion sequences. The certificates should differ.